
==== Front
Ann Surg Oncol
Ann Surg Oncol
Annals of Surgical Oncology
1068-9265
1534-4681
Springer International Publishing Cham

38940899
15682
10.1245/s10434-024-15682-2
Breast Oncology
Persistent Pain After Breast Cancer Treatment, an Underreported Burden for Breast Cancer Survivors
http://orcid.org/0009-0001-6824-3354
Strijbos Bo T. M. MD bo.strijbos@radboudumc.nl

1
Janssen Loes PhD 1
Voogd Adri C. PhD 2
Zwaans Willem A. R. MD, PhD 13
Roumen Rudi M. H. MD, PhD 1
Maaskant-Braat Adriana J. G. MD, PhD 1
1 https://ror.org/02x6rcb77 grid.414711.6 0000 0004 0477 4812 Department of Surgical Oncology, Máxima Medical Center, Veldhoven, The Netherlands
2 https://ror.org/02jz4aj89 grid.5012.6 0000 0001 0481 6099 Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
3 https://ror.org/02jz4aj89 grid.5012.6 0000 0001 0481 6099 NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
28 6 2024
28 6 2024
2024
31 10 67536763
5 9 2023
12 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Many patients who have undergone surgery experience persistent pain after breast cancer treatment (PPBCT). These symptoms often remain unnoticed by treating physician(s), and the pathophysiology of PPBCT remains poorly understood. The purpose of this study was to determine prevalence of PPBCT and examine the association between PPBCT and various patient, tumor, and treatment characteristics.

Patients and Methods

We conducted a questionnaire-based cross-sectional study enrolling patients with breast cancer treated at Máxima Medical Center between 2005 and 2016. PPBCT was defined as pain in the breast, anterior thorax, axilla, and/or medial upper arm that persists for at least 3 months after surgery. Tumor and treatment characteristics were derived from the Dutch Cancer Registry and electronic patient files.

Results

Between February and March 2019, a questionnaire was sent to 2022 women, of whom 56.5% responded. Prevalence of PPBCT among the responders was 37.9%, with 50.8% reporting moderate to severe pain. Multivariable analyses showed that women with signs of anxiety, depression or a history of smoking had a higher risk of experiencing PPBCT. Women aged 70 years or older at diagnosis were significantly less likely to report PPBCT compared with younger women. No significant association was found between PPBCT and treatment characteristics, including type of axillary surgery and radiotherapy.

Conclusions

A considerable percentage of patients with breast cancer experience PPBCT. Women with signs of anxiety or depression and women with a history of smoking are more likely to report PPBCT. Further research is required to understand the underlying etiology and to improve prevention and treatment strategies for PPBCT.

Keywords

Breast cancer
Breast cancer treatment
Pain
Postoperative
Persistent pain
Surgery breast
issue-copyright-statement© Society of Surgical Oncology 2024
==== Body
pmcBreast cancer is the most common cancer among women. In 2021, there were approximately 18,000 women with newly diagnosed breast cancer in the Netherlands,1,2 and breast cancer is the most common cause of death for women aged 30–59 years.3 Women with a diagnosis of nonmetastatic early-stage breast cancer will, in general, undergo primary surgery of the breast, either lumpectomy or mastectomy, as well as a sentinel node biopsy procedure with or without radiation therapy. Depending on tumor characteristics, adjuvant systemic therapy consisting of endocrine therapy, chemotherapy and/or targeted therapy, may be offered. There is also the option for neo-adjuvant therapy.4 The 5-year relative survival rate for patients with breast cancer in the Netherlands has increased to approximately 88% as a result of earlier diagnosis owing to improved screening and treatment strategies.2,3 Due to this decrease in mortality rate, the focus has shifted toward improvement of physical function and quality of life by reducing the risk of treatment-related morbidity.5,6 In more recent years, clinical care of patients with breast cancer has further shifted toward a more patient-centered approach and more attention is given to patient-reported outcome measures (PROMs). PROMs are defined as feedback on a patient’s health condition, such as symptoms and quality of life, provided directly by the individual patient without external interpretation.7 This shift has also contributed to the increased focus on morbidity.8

A large proportion of patients surviving breast cancer who have undergone surgery experience persistent pain. Often this pain is localized in different regions such as the breast, axilla, upper arm, and the anterior and/or lateral chest wall.14 This has become an increasingly recognized condition that affects between 25 and 60% of these patients.9–11 The International Association for the Study of Pain (IASP) defines chronic post-surgical pain (CPSP) as pain that develops after a surgical procedure and persists beyond the normal healing process of 3 months.12 There are no universally accepted diagnostic criteria for persistent pain after breast cancer treatment (PPBCT). Currently, the criteria of the IASP for CPSP are used, unofficially, to define and diagnose PPBCT.13 PPBCT can predominantly be characterized as neuropathic pain.9,14,15 Several studies suggest that persistent neuropathic pain is triggered by peripheral nerve injury caused during surgical dissection or because of postoperative inflammation.5,16 Other studies suggest that chemotherapy and radiation therapy contribute to the development of persistent pain.13,17,18 Studies show that psychosocial factors, such as catastrophizing, anxiety, depression, somatization, and sleep quality, can play an important role in the development of PPBCT.19,20 However, the exact pathophysiology is poorly understood, which hampers the preoperative screening, counseling and management of patients experiencing PPBCT and also explains why PPBCT is often not recognized. Therefore, it is of clinical interest to identify potential risk factors that contribute to the reporting and development of PPBCT. Previous studies have reported risk factors for PPBCT, and these include axillary lymph node dissection,9,10,22,23 younger age,9,10,23 radiotherapy,10,23 acute postoperative pain,10 obesity (body mass index > 30),23 lower socio-economic status,9 endocrine treatment in post-menopausal woman,22 and non-Caucasian ethnicity.9 However, inconsistent results were found, with some studies showing negative associations and others reporting no associations at all.24,25 In particular, there is little agreement among studies in relation to the role of obesity in PPBCT.25

These contradictory results make it difficult to draw definitive conclusions concerning determinants of PPBCT. Accordingly, the purpose of this study was to examine the prevalence of PPBCT and the association between PPBCT and various patient, tumor, and treatment characteristics in women treated for breast cancer in a single institution in the Netherlands.

Patients and Methods

Study Eligibility Criteria

This study was designed as a retrospective questionnaire-based cohort study of patients who completed breast cancer surgery at Máxima Medical Center (Máxima MC), a large non-university teaching hospital in the Netherlands, between January 2005 and December 2016. Inclusion criteria were women aged 18 years or older at the time of diagnosis who had completed surgery for breast cancer more than 3 months prior to assessment. Patients with an inability to fill in the questionnaires due to a language barrier, patients who were already deceased, and patients with cognitive impairment were excluded from the study. Written informed consent was obtained from all participants.

Data Collection

Patient data were retrieved from the population-based Eindhoven Cancer Registry. This registry records data from all newly diagnosed patients with cancer in the southeast region of the Netherlands, an area with approximately 2.4 million inhabitants. Eligible patients were identified and questionnaires were sent between February and March 2019.

The primary outcome was the prevalence of PPBCT. PPBCT was defined as pain located in the area of the breast, axilla, the lateral thorax, and/or the arm on the operated side of the body, persisting for more than 3 months after end of treatment. Patients were asked to fill out a questionnaire and were asked if they experienced PPBCT. Additionally, they rated their pain intensity on a zero to ten numerical rating scale (NRS) and a verbal rating scale (VRS). Pain was categorized as mild when the value on the NRS was less than or equal to 4. Values greater than 4 were categorized as moderate to severe pain. Questionnaires also included a portion of the McGill Pain Questionnaire Dutch Language Version (MPQ-DLV), questions from the Douleur Neuropathique (DN4), a section of the Multidimensional Pain Inventory Dutch Language Version (MPI-DLV), the Hospital Anxiety and Depression scale (HADS), and questions regarding pain management and substance use.

Different cutoff values were utilized in the questionnaires. In this study, participants completed a modified version of the DN4 questionnaire, which consisted of seven questions focusing solely on the presence of sensory symptoms associated with neuropathic pain. If a participant responded “Yes” to any of these questions, it was scored as positive for that particular symptom. The total score was then calculated by summing the positive responses. A score of 4 or higher was used as the cutoff value to classify the pain as neuropathic. The scoring system of the HADS consists of 14 items divided into two subscales: anxiety and depression. Each item is scored on a 4-point scale, with higher scores indicating higher levels of anxiety and depression. The total score for each subscale ranges from 0 to 21, with scores of 8 or higher considered clinically significant and indicative for the presence of anxiety or depression. Sent questionnaires contained a cover letter, two consent forms, and a stamped and addressed reply envelope. Patients were given the opportunity to fill out the questionnaire online, and a gentle reminder was sent 4 weeks later, if needed. Additional data on patient, tumor, and treatment characteristics were provided by the Dutch Cancer Registry, based on the pathology reports, and from the electronic patient records. Data were managed using Research Manager (data management software, Cloud9 software, Deventer).

Statistical Analyses

The prevalence of PPBCT and various pain characteristics were assessed and presented as descriptive statistics, as appropriate. Patients were stratified into two categories: patients experiencing PPBCT and patients not experiencing PPBCT. These categories were based on the dichotomous (yes/no) outcome of the first question from the questionnaire, which was: “Do you currently have pain in the area of the chest, axilla, lateral side of the body, or arm on the side where you had breast cancer surgery?”. Patient, tumor, treatment, and pain characteristics were compared between groups using Pearson’s χ2 test or Fisher’s exact test, as appropriate. For categorical data an independent-samples t-test was used to compare continuous variables. Variables described in the literature as potentially associated with PPBCT were first assessed in a univariate logistic regression analysis. Variables that showed a significant association with PPBCT in the univariate analyses (p-value < 0.1) were entered in a multivariate analysis. Odds ratios (OR), 95% confidence intervals (95% CI), and corresponding p-values were calculated. A p-value of < 0.05 was considered statistically significant. Data analysis was done using SPSS® version 22 (IBM Corp, released 2020, Armonk, New York, USA).

Ethical Approval

All procedures were conducted in accordance with institutional guidelines. The Ethics Committee of Máxima Medical Centre concluded that the rules laid down in the medical research involving human subjects act (also known by its Dutch abbreviation WMO) did not apply to this study (METC N18.151), and a formal ethical approval was waived.

Results

Response Rate

Questionnaires, including an informed consent form, were sent to 2022 eligible patients between February and March 2019. A total of 1142 patients completed the questionnaires (56.5% response rate). Ultimately, 1048 patients were included in this study (51.8%). Figure 1 contains a flow chart of the questionnaire response progress and the patients included in this study.Fig. 1 Flow-chart of questionnaire response and included patients

Prevalence of PPBCT and Overall Characteristics

Overall, 397 (37.9%) patients reported PPBCT, and 651 (62.1%) patients reported no pain. Tables 1, 2 and 3 show the patient, tumor and treatment characteristics of the included patients.Table 1 Patient characteristics

Patient characteristics	Number of patients (n)	No pain (n = 651, 62.1%)	Persistent pain (n = 397, 37.9%)	p-Value	
Age at diagnosis, years (SD) (n = 1048, 100%)		59.53 (±11.525)	56.16 (±10.724)	< 0.001•	
< 40	57	29 (4.5)	28 (7.1)	
40–50	213	118 (18.1)	95 (23.9)	
50–70	623	387 (59.4)	236 (59.4)	
≥ 70	155	117 (18.0)	38 (9.6)	
BMI at baseline, kg/m2 (SD) (n = 696, 66.4%)	0.322	
< 18	8	4 (0.9)	4 (1.5)		
18–25	330	206 (48.1)	124 (46.3)		
25–30	232	145 (33.9)	87 (32.5)		
30–35	91	55 (12.9)	36 (13.4)		
35–40	20	13 (3.0)	7 (2.6)		
≥ 40	15	5 (1.2)	10 (3.7)		
Missing	352	223	129		
Smoking (n = 1035, 98.8%)	0.010•	
Yes	93	55 (8.6)	38 (9.6)		
No	715	463 (72.3)	252 (63.8)		
Quit	227	122 (19.1)	105 (26.6)		
Missing	13	11	2		
Drinking alcohol (n = 1039, 99.1%)	0.380	
Yes	604	380 (59.2)	224 (56.4)		
No	435	262 (40.8)	173 (43.6)		
Missing	9	9	0		
Menopausal stage (n = 654, 62.4%)	0.004•	
Premenopausal	162	95 (23.2)	67 (27.5)		
Perimenopausal	59	27 (6.6)	32 (13.1)		
Postmenopausal	433	288 (70.2)	145 (59.4)		
Missing	394	241	153		
Anxiety (n = 1015, 96.9%)	0.000•	
Yes (HADS ≥ 8)	200	83 (13.2)	117 (30.2)		
No (HADS < 8)	815	544 (86.8)	271 (69.8)		
Missing	33	24	9		
Depression (n = 1022, 97.5%)	0.000•	
Yes (HADS ≥ 8)	121	44 (7.0)	77 (19.6)		
No (HADS < 8)	901	585 (93.0)	316 (80.4)		
Missing	26	22	4		
SD Standard deviation, BMI Body mass index. “•” indicates statistical significance. Note: variables as number (percentage)

Table 2 Tumor characteristics

Tumor characteristics	Number of patients (n)	No pain (n = 651, 62.1%)	Persistent pain (n = 397, 37.9%)	p-Value	
Breast cancer side (n = 1048, 100%)	0.800	
Left	540	331 (50.8)	209 (52.6)		
Right	487	306 (47.0)	181 (45.6)		
Double sided	21	14 (2.2)	7 (1.8)		
Topography (n = 1048, 100%)	0.741	
Central part	43	26 (4.0)	17 (4.3)		
Medial upper quadrant	140	87 (13.4)	53 (13.4)		
Medial lower quadrant	56	32 (4.9)	24 (6.0)		
Lateral upper quadrant	373	231 (35.5)	142 (35.8)		
Lateral lower quadrant	89	57 (8.8)	32 (8.1)		
Mamma overlay	327	202 (31.0)	125 (31.5)		
Other*	20	16 (2.5)	4 (1.0)		
Morphology (n = 1048, 100%)	0.472	
Ductal,	808	509 (78.2)	299 (75.3)		
Lobular/mixed	184	108 (16.6)	76 (19.1)		
Mucinous/tubular/medullary	38	25 (3.8)	13 (3.3)		
Other	18	9 (1.4)	9 (2.3)		
TNM stadium (n = 1048, 100%)	0.036•	
1	172	113 (17.4)	59 (14.9)		
1A	357	241 (37.0)	116 (29.2)		
1B	29	19 (2.9)	10 (2.5)		
2A	248	150 (23.0)	98 (24.7)		
2B	133	69 (10.6)	64 (16.1)		
3A	63	32 (4.9)	31 (7.8)		
3B	11	5 (0.8)	6 (1.5)		
3C	30	19 (2.9)	11 (2.8)		
4	5	3 (0.5)	2 (0.5)		
Estrogen receptor (n = 1048, 100%)	0.525	
Positive	886	545 (83.7)	341 (85.9)		
Negative	153	101 (15.5)	52 (13.1)		
Unknown	9	5 (0.8)	4 (1.0)		
Progesterone receptor (n = 1048, 100%)	0.206	
Positive	710	434 (66.7)	276 (69.5)		
Negative	321	209 (32.1)	112 (28.2)		
Unknown	17	8 (1.2)	9 (2.3)		
Her2Neu receptor (n = 1048, 100%)	0.894	
Positive	124	75 (11.5)	49 (12.3)		
Negative	893	556 (85.4)	337 (84.9)		
Unknown	31	20 (3.1)	11 (2.8)		
Molecular subtypes (n = 1048, 100%)	0.552	
Triple-negative	109	74 (11.4)	35 (8.8)		
Luminal A	777	478 (73.4)	299 (75.3)		
Luminal B	88	52 (8.0)	36 (9.1)		
HER2-enriched	33	23 (3.5)	10 (2.5)		
Unknown	41	24 (3.7)	17 (4.3)		
SD standard deviation, TNM tumor–node–metastasis, Her2Neu human epidermal growth receptor.

*“Other” is a combined category consisting of the following parts: nipple/areola, axillary spur, and mamma not specified; “•” indicates statistical significance. Note: variables as number (percentage)

Table 3 Treatment characteristics

Treatment characteristics	Number of patients (n)	No pain (n = 651, 62.1%)	Persistent pain (n = 397, 37.9%)	p-Value	
Time since primary surgery, years (SD) (n = 1048, 100%)		7.23 (±3.48)	7.26 (±3.39)	0.913	
0–5 years	331	211 (32.4)	120 (30.2)		
5–10 years	462	276 (42.4)	186 (46.9)		
10–15 years	255	164 (25.2)	91 (22.9)		
Type of definitive surgery (n = 1048, 100%)	0.941	
Breast-conserving surgery	698	433 (66.5)	265 (66.8)		
Mastectomy	266	167 (25.7)	99 (24.9)		
Mastectomy combined with reconstructive surgery	84	51 (7.8)	33 (8.3)		
Type of axillary surgery (n = 1048, 100%)	0.000•	
SNB alone	744	486 (74.7)	258 (65.0)		
SNB + ALND	122	54 (8.3)	68 (17.1)		
ALND alone	145	86 (13.2)	59 (14.9)		
None	37	25 (3.8)	12 (3.0)		
Chemotherapy (n = 1048, 100%)	0.000•	
Yes	473	261 (40.1)	212 (53.4)		
No	575	390 (59.9)	185 (46.6)		
Timing of chemotherapy (n = 473, 45.1%)	0.590**	
Neoadjuvant	162	92 (35.2)	70 (33)		
Adjuvant	310	168 (64.4)	142 (67)		
Combined	1	1 (0.4)	0 (0)		
Type of chemotherapy (n = 473, 45.1%)	0.228	
TAC	297	162 (62.1)	135 (63.7)		
FEC	119	67 (25.7)	52 (24.5)		
TAC + FEC	30	13 (5.0)	17 (8.0)		
Other/unknown	27	19 (7.3)	8 (3.8)		
Radiotherapy (n = 1048, 100%)	0.122	
Yes	821	500 (76.8)	321 (80.9)		
No	227	151 (23.2)	76 (19.1)		
Localization local radiotherapy (n = 821, 78.3%)	0.055***	
Mamma	697	433 (86.6)	264 (82.2)		
Chest wall	121	64 (12.8)	57 (17.8)		
Only locoregional	3	3 (0.6)	0 (0)		
Locoregional radiotherapy (n = 821, 78.3%)	0.168	
Axilla	80	49 (9.8)	31 (9.7)		
Periclavicular	25	14 (2.8)	11 (3.4)		
Axilla and periclavicular	43	21 (4.2)	22 (6.9)		
None	611	371 (74.2)	240 (74.8)		
Other****	62	45 (9.0)	17 (5.3)		
Endocrine therapy (n = 1048, 100%)	0.025•	
Yes	566	334 (51.3)	232 (58.4)		
No	482	317 (48.7)	165 (41.6)		
Targeted therapy (n = 1048, 100%)	0.558	
Yes	119	71 (10.9)	48 (12.1)		
No	929	580 (89.1)	349 (87.9)		
SD standard deviation, SNB sentinel node biopsy, ALND axillary lymph node dissection, TAC combination of taxotere, adriamycin and cyclophosphamide, FEC combination of fluorouracil, epirubicin, and cyclophosphamide.

**To create this p-value, the patients with combined treatment were excluded from analysis. ***To create this p-value, the patients with only locoregional treatment were excluded from analysis.

****“Other” is a combined category consisting of the patient with locoregional radiotherapy in the combined regions of “periclavicular + parasternal,” “axilla + periclavicular + parasternal,” “periclavicular + neck,” and “unknown.” “•” indicates statistical significance. Note: variables as number (percentage)

Pain characteristics for all 397 (37.9%) patients with PPBCT are described in Table 4. Of these patients, 50.8% categorized the pain intensity as moderate to severe based on a numerical rating scale. Almost half of the patients (43.2%) noted that the pain was always present but varied in intensity, and 19.1% characterized their pain as neuropathic based on the DN4 questionnaire.Table 4 Pain characteristics

Pain characteristics	Persistent pain (n = 397)	
Most painful location	
Breast	184 (46.4)	
Lateral side of thorax	75 (19.0)	
Axilla	66 (16.7)	
Arm	51 (12.9)	
Unknown	19 (4.8)	
NRS scale, median (25%; 75%)	5 (3; 6)	
Mild (≤ 4)	194 (49.2)	
Moderate/severe (> 4)	200 (50.8)	
VRS scale	
None or mild, n (%)	170 (43.4)	
Moderate, n (%)	172 (43.9)	
Severe and very severe, n (%)	50 (12.8)	
Duration of pain, years (SD)	5.6 (±3.8)	
Start of pain	
Sudden	107 (27.9)	
Gradually	276 (72.1)	
Pain located at one spot only	
Yes	327 (82.8)	
No	68 (17.2)	
Radiation of pain	
Yes	119 (30.4)	
No	273 (69.6)	
Shooting pain that changes location	
Yes	53 (13.6)	
No	336 (84.4)	
Description of pain	
Pain comes in attacks	158 (41.1)	
Pain varies in intensity, but always present	166 (43.2)	
Pain continuously present	60 (15.6)	
Neuropathic pain	
Yes (DN4 score ≥ 4)	61 (19.1)	
No (DN4 score < 4)	259 (80.9)	
Interference with daily life score (0–54), mean (SD)	16.4 (±15.2)	
Mild (NRS ≤ 4), mean (SD)	9.6 (±11.8)	
Moderate/severe (> 4), mean (SD)	23.0 (±15.4)	
Need for pain medication	
Yes	123 (31.1)	
No	272 (68.9)	
Type of pain medication	
Paracetamol	48 (44.4)	
NSAID	13 (12.0)	
Opioids	10 (9.3)	
Other*	37 (34.3)	
NRS numerical rating scale, VRS verbal rating scale, SD standard deviation, DN4 Douleur Neuropathique, NSAID nonsteroidal anti-inflammatory analgesic.

*“Other” is a combined category consisting of various combinations of the above-mentioned analgesic medication with or without additional neuropathic pain medication (pregabalin and/or amitriptyline). Note: variables as number (percentage)

Risk Factors of PPBCT

Univariate analysis identified eight variables potentially associated with the reporting of PPBCT (Table 5). These were age at diagnosis of 50 years or older, body mass index (BMI) above 40 kg/m2, patients having quit smoking, anxiety, depression, axillary lymph node dissection, chemotherapy, and endocrine therapy.Table 5 Univariate and multivariate analysis

Risk factor	Univariate analysis	Multivariate analysis (n = 999)	
OR (95% CI)	p-Value	OR (95% CI)	p-Value	
Age at diagnosis, years	
< 40	1		1		
40–50	0.83 (0.46–1.50)	0.543	0.74 (0.40–1.38)	0.343	
50–70	0.63 (0.37–1.09)	0.098*	0.64 (0.36–1.16)	0.145	
≥ 70	0.34 (0.18–0.64)	0.001*	0.35 (0.17–0.74)	0.006•	
BMI at baseline, kg/m2	
18–25	1		1		
< 18	1.66 (0.41–6.67)	0.478	1.86 (0.39–8.85)	0.433	
25–30	1.00 (0.71–1.41)	0.985	1.11 (0.76–1.61)	0.590	
30–35	1.09 (0.68–1.75)	0.730	1.05 (0.62–1.76)	0.859	
35–40	0.90 (0.35–2.30)	0.817	0.74 (0.26–2.11)	0.574	
≥ 40	3.32 (1.11–9.95)	0.032*	4.43 (1.28–15.40)	0.019•	
Unknown	0.96 (0.70–1.31)	0.802	1.02 (0.72–1.45)	0.918	
Smoking	
No	1		1		
Yes	1.27 (0.82–1.97)	0.289	1.06 (0.65–1.72)	0.821	
Quit	1.58 (1.17–2.14)	0.003*	1.55 (1.12–2.14)	0.008•	
Anxiety	
No (HADS < 8)	1		1		
Yes (HADS ≥ 8)	2.83 (2.06–3.88)	0.000*	2.09 (1.44–3.05)	0.000•	
Depression	
No (HADS < 8)	1		1		
Yes (HADS ≥ 8)	3.24 (2.18–4.81)	0.000*	2.51 (1.55–4.07)	0.000•	
Type of axillary surgery	
None	1		1		
SNB alone	1.11 (0.55–2.24)	0.779	0.92 (0.43–1.97)	0.832	
ALND alone	1.43 (0.67–3.07)	0.359	1.00 (0.43–2.33)	0.993	
SNB + ALND	2.62 (1.21–5.70)	0.015*	1.91 (0.81–4.50)	0.141	
Chemotherapy	
No	1		1		
Yes	1.71 (1.33–2.20)	0.000*	1.17 (0.83–1.66)	0.374	
Radiotherapy	
No	1				
Yes	1.28 (0.94–1.74)	0.123			
Endocrine therapy	
No	1		1		
Yes	1.33 (1.04–1.72)	0.025*	1.05 (0.78–1.43)	0.740	
BMI body mass index, HADS hospital anxiety and depression scale, SNB sentinel node biopsy, ALND axillary lymph node dissection.

*p-Value < 0.1; “•” indicates statistical significance

Multivariable logistic regression analysis showed that age at diagnosis of 70 years or older (OR 0.35, p = 0.006, for age ≥ 70 versus < 40 years) was independently associated with PPBCT and that the risk of PPBCT was lower in this age category. The categories of BMI above 40 kg/m2 (OR 4.43, p = 0.019 for BMI ≥ 40 versus BMI between 18 and 25 kg/m2), having quit smoking (OR 1.55, p = 0.008, for those who quit smoking compared with nonsmokers), anxiety (OR 2.09, p < 0.001, for HADS ≥ 8 versus < 8) and depression (OR 2.51, p < 0.001, for HADS ≥ 8 versus < 8) were also independently associated with a higher risk of PPBCT (Table 5).

Discussion

To our knowledge, this work represents one of the largest studies to date describing PPBCT, encompassing a thorough examination of potential risk factors, including demographic, treatment, and psychosocial factors. We investigated 1048 women who had undergone surgical therapy for breast cancer with the aim of examining the prevalence of PPBCT and the association between PPBCT and various patient, tumor, and treatment characteristics. Thus, by using data from the Eindhoven Cancer Registry, we were able to obtain results based on a large, unselected, population-based patient population.

Our findings demonstrate a prevalence of PPBCT of 38% in the population studied in this report. Previous studies that investigated the prevalence of PPBCT have reported a prevalence ranging from 20 to 60%.9–11 It is likely that part of this wide range in reported prevalence is caused by a lack of consistency in the definition of PPBCT applied in these reports. We defined PPBCT as pain located in the breast, lateral thorax, axilla, and/or medial upper arm, with or without sensory disturbances, persisting for more than 3 months after surgical breast cancer treatment. Some studies have defined PPBCT as “any pain mentioned by patients” lasting for at least 2–6 months after surgical intervention,8,10 whereas one study used a cutoff value of 4 on a numerical rating scale 0–10.11 This latter study reported a prevalence of 38.3% in a cohort of 261 patients.11 Our results corroborate these previous studies concerning the prevalence of PPBCT in surgical patients with breast cancer.

In the patient population studied in this report, 50.8% of women with PPBCT characterize the pain as moderate to severe (NRS > 4). Our findings show that pain is more likely to be constantly present (43.2%) and to have a gradual onset (72.1%). The prevalence of neuropathic pain was 19%. In their 2017 systematic review, Ilhan et al. reported that the prevalence of neuropathic pain among women treated for early-stage breast cancer ranged between 3.1 and 50.0%.28 Based on previously reported findings9,14,15 and the present results, PPBCT can be characterized as moderate to severe pain (NRS > 4) with a neuropathic pain component. Nevertheless, there still remains a need for detailed physical examination of patients with signs of neuropathic pain because data used in this study were only based on questionnaires without quantitative sensory testing. Extensive physical examination may provide a rational basis for mechanism-based interventions for PPBCT in the future. Additionally, while the DN4 employs an accepted cutoff value of 4 for identifying neuropathic pain, it is crucial to recognize that this threshold was primarily designed and validated for diagnosing neuropathic pain in general, rather than specifically in the context of post-surgical injury. Thus, we recommend considering this aspect in future studies.

As stated before, studies that examined the significance of risk factors associated with PPBCT provided contradicting results. In one of the larger studies, which included 3253 patients with a 2-year follow-up, 47% of the respondents reported pain.15 Of note, this previous study showed that younger patients (< 40 years old), patients treated with adjuvant radiotherapy and patients who underwent axillary lymph node dissection had a significantly higher risk of developing PPBCT. Our study also demonstrated that older patients (age > 70 years at diagnosis) experienced significantly less pain in comparison with younger patients. The univariate analyses used in this report established a strong association between various treatments such as type of axillary surgery, chemotherapy, and endocrine therapy and PPBCT, which is consistent with other studies.6,10,15,23 However, these associations were no longer statistically significant after adjustment for confounders in a multivariable analysis.

Our findings show a significant association between a BMI above 40 kg/m2 and PPBCT, and between psychosocial status, including the variables anxiety and depression, and PPBCT. These findings are in concordance with existing literature.15,21,22 However, no hard conclusions can be drawn regarding a causal pathway that underlies these associations. Because our study used a cross-sectional design, and there were no questions regarding BMI included in the distributed patient questionnaires, there was a considerable amount of missing information on BMI in our study. It also has to be noted that the subgroup of patients with BMI > 40, consisted of only 15 patients, explaining the wide 95% confidence interval in the calculated odds ratio. Regarding the association between anxiety, depression, and PPBCT, some evidence is emerging that behavioral interventions directed at these psychological conditions during the peri- and postoperative period may help prevent the onset of chronic postoperative pain.21 The identification of these conditions as potential predictors of PPBCT underscores the importance of preoperative screening. Implementing standardized preoperative assessments that include screening for psychosocial factors can aid in identifying patients at high risk of developing PPBCT and facilitate the application to targeted preventive therapies. Large-scale therapeutic interventions, conducted in relevant subpopulations, are required to outline rational strategies for prevention and treatment of PPBCT. Hopefully, the ongoing AMAZONE study,30 a multicenter randomized controlled trial investigating the effect of online cognitive behavioral therapy (e-CBT) on the prevalence of PPBCT, will better clarify potentially beneficial treatment strategies.

Surprisingly, radiotherapy did not show an association with the reporting of PPBCT in our univariate analyses. We included this variable on the basis of contradictory evidence in the literature. Specifically, some studies concluded that radiotherapy could be related to the development of PPBCT,10,23 whereas another study found no association.6 It is generally accepted that women who receive radiotherapy are at risk of late side effects including radiation-induced fibrosis. This is an irreversible condition in which excessive formation of fibrous connective tissue causes structural and functional changes29 that are thought to induce neuropathy and neuropathic pain. Further prospective research, taking into account the radiation techniques and doses and the irradiated fields,31 is needed to explore these contradictory findings and to establish conclusive evidence regarding the relationship between radiotherapy and PPBCT.

The strengths of this study are that it is based on a large representative cohort that reflects usual breast cancer care in the Netherlands and that it is large enough to provide reasonably precise risk estimates of the prevalence of PPBCT and the strength of the association with patient, tumor, and treatment variables. Our results on the effect of axillary surgery, chemotherapy, and endocrine therapy demonstrate the importance of multivariate analyses to unravel pain risk factors independent of those linked to persistent pain. Many previous studies have been published based on relatively small sample sizes that often focused on only one or two variables.11,26,27 The questionnaires used in this study covered not only the severity or intensity of pain but also many other aspects regarding treatment and patient characteristics. Incorporating patient-reported outcome measures (PROMS) into preoperative assessment can provide valuable insights into patients’ experiences and perceptions of pain, thus aiding in individualized treatment planning and monitoring of postoperative outcomes. This approach aligns with the growing emphasis on patient-centered care and personalized medicine.

The principal limitation of this study is its cross-sectional design. We did not follow up patients over time, and thus, we are unable to comment on how the reported pain develops over time. Another limitation is that some of the included patients underwent breast cancer treatment more than 10 years ago. This introduces the potential for bias, as these patients may report pain differently compared with those who were treated more recently. This could be due to several factors, including changing perceptions of pain over time, differences in treatment modalities, and advancements in pain management techniques over the years. Therefore, it is important to consider this variability when interpreting the results, as the experience and reporting of pain may vary among patients who underwent treatment during different time periods. Additionally, the cross-sectional design used in this study does not allow us to draw conclusions regarding causality but can merely describe associations between various variables and persistent pain. Another limitation of this study is the relatively high nonresponder rate of 43.5%, which may introduce potential selection bias. However, it is noteworthy that, despite this limitation, a considerable number of participants, comprising more than half of the total, did actively respond and provide valuable data for analysis.

This large, cross-sectional, retrospective cohort study conducted in a Dutch teaching hospital showed that PPBCT is a frequently observed phenomenon among breast cancer survivors, affecting 37.9% of patients. Anxiety, depression, and a history of smoking are significantly associated with increased reporting of PPBCT, though causation is not implied. Patients aged 70 or older at diagnosis are less susceptible. Treatment type may not impact PPBCT reporting significantly, but further research is needed. Prospective studies are necessary to identify potential intervention targets for PPBCT prevention and treatment. These findings emphasize the importance of understanding PPBCT and developing targeted interventions to improve patient well-being, particularly during preoperative counseling. Proactive pain management strategies can potentially mitigate the burden of PPBCT and enhance the overall quality of care for patients with breast cancer undergoing surgery.

Acknowledgement

The authors would like to thank Carolien Bode for her contribution to the initiation of this study and sending out the questionnaires.

Funding

None.

Disclosure

The authors have nothing to disclose. There were no conflicts of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. VZinfo. 2022. https://www.volksgezondheidenzorg.info/onderwerp/borstkanker/cijfers-context/huidige-situatie#node-het-vóórkomen-van-borstkanker Accessed 08 Mar 2020.
2. Integraal kankercentrum Nederland. 2022. https://iknl.nl/borstkankercijfers Accessed 13 Apr 2023.
3. VZinfo. 2022. https://www.volksgezondheidenzorg.info/onderwerp/borstkanker/cijfers-context/sterfte-en-overleving#node-sterfte-borstkanker Accessed 04 Sept 2020.
4. Taghian A, Merajver SD. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer. In: UpToDate. 2021. https://www.uptodate.com/contents/overview-of-the-treatment-of-newly-diagnosed-non-metastatic-breast-cancer Accessed 13 Apr 2023.
5. Khan JS Hodgson N Choi S Perioperative pregabalin and intraoperative lidocaine infusion to reduce persistent neuropathic pain after breast cancer surgery: a multicenter, factorial, randomized, controlled pilot trial J Pain. 2019 20 8 980 993 10.1016/j.jpain.2019.02.010 30844507
Khan JS, Hodgson N, Choi S, et al. Perioperative pregabalin and intraoperative lidocaine infusion to reduce persistent neuropathic pain after breast cancer surgery: a multicenter, factorial, randomized, controlled pilot trial. J Pain. 2019;20(8):980–93. 10.1016/j.jpain.2019.02.010.30844507
6. Mejdahl MK Andersen KG Gärtner R Kroman N Kehlet H Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study BMJ. 2013 346 f1865 10.1136/bmj.f1865 23580693
Mejdahl MK, Andersen KG, Gärtner R, Kroman N, Kehlet H. Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study. BMJ. 2013;346:f1865. 10.1136/bmj.f1865.23580693
7. van Egdom LSE Oemrawsingh A Verweij LM Implementing patient-reported outcome measures in clinical breast cancer care: a systematic review Value Health. 2019 22 10 1197 1226 10.1016/j.jval.2019.04.1927 31563263
van Egdom LSE, Oemrawsingh A, Verweij LM, et al. Implementing patient-reported outcome measures in clinical breast cancer care: a systematic review. Value Health. 2019;22(10):1197–226. 10.1016/j.jval.2019.04.1927.31563263
8. Riis CL Bechmann T Jensen PT Coulter A Steffensen KD Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review Patient Relat Outcome Meas. 2019 10 117 127 10.2147/PROM.S195296 30988648
Riis CL, Bechmann T, Jensen PT, Coulter A, Steffensen KD. Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review. Patient Relat Outcome Meas. 2019;10:117–27. 10.2147/PROM.S195296.30988648
9. Chiang DLC Rice DA Helsby NA Somogyi AA Kluger MT The prevalence, impact, and risk factors for persistent pain after breast cancer surgery in a New Zealand population Pain Med. 2019 20 9 1803 1814 10.1093/pm/pnz049 30889241
Chiang DLC, Rice DA, Helsby NA, Somogyi AA, Kluger MT. The prevalence, impact, and risk factors for persistent pain after breast cancer surgery in a New Zealand population. Pain Med. 2019;20(9):1803–14. 10.1093/pm/pnz049.30889241
10. Wang L Guyatt GH Kennedy SA Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies CMAJ. 2016 188 14 E352 E361 10.1503/cmaj.151276 27402075
Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;188(14):E352–61. 10.1503/cmaj.151276.27402075
11. Andersen KG Duriaud HM Jensen HE Kroman N Kehlet H Predictive factors for the development of persistent pain after breast cancer surgery Pain. 2015 156 12 2413 2422 10.1097/j.pain.0000000000000298 26176893
Andersen KG, Duriaud HM, Jensen HE, Kroman N, Kehlet H. Predictive factors for the development of persistent pain after breast cancer surgery. Pain. 2015;156(12):2413–22. 10.1097/j.pain.0000000000000298.26176893
12. Schug SA Lavand'homme P Barke A The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain Pain. 2019 160 1 45 52 10.1097/j.pain.0000000000001413 30586070
Schug SA, Lavand’homme P, Barke A, et al. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. Pain. 2019;160(1):45–52. 10.1097/j.pain.0000000000001413.30586070
13. Khan JS Ladha KS Abdallah F Clarke H Treating persistent pain after breast cancer surgery Drugs. 2020 80 1 23 31 10.1007/s40265-019-01227-5 31784873
Khan JS, Ladha KS, Abdallah F, Clarke H. Treating persistent pain after breast cancer surgery. Drugs. 2020;80(1):23–31. 10.1007/s40265-019-01227-5.31784873
14. Jung BF Ahrendt GM Oaklander AL Dworkin RH Neuropathic pain following breast cancer surgery: proposed classification and research update Pain. 2003 104 1–2 1 13 10.1016/s0304-3959(03)00241-0 12855309
Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003;104(1–2):1–13. 10.1016/s0304-3959(03)00241-0.12855309
15. Gärtner R Jensen MB Nielsen J Ewertz M Kroman N Kehlet H Prevalence of and factors associated with persistent pain following breast cancer surgery [published correction appears in JAMA. 2012 Nov 21;308(19):1973] JAMA. 2009 302 18 1985 1992 10.1001/jama.2009.1568 19903919
Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery [published correction appears in JAMA. 2012 Nov 21;308(19):1973]. JAMA. 2009;302(18):1985–92. 10.1001/jama.2009.1568.19903919
16. Deumens R Steyaert A Forget P Prevention of chronic postoperative pain: cellular, molecular, and clinical insights for mechanism-based treatment approaches Prog Neurobiol. 2013 104 1 37 10.1016/j.pneurobio.2013.01.002 23410739
Deumens R, Steyaert A, Forget P, et al. Prevention of chronic postoperative pain: cellular, molecular, and clinical insights for mechanism-based treatment approaches. Prog Neurobiol. 2013;104:1–37. 10.1016/j.pneurobio.2013.01.002.23410739
17. Gottrup H Andersen J Arendt-Nielsen L Jensen TS Psychophysical examination in patients with post-mastectomy pain Pain. 2000 87 3 275 284 10.1016/S0304-3959(00)00291-8 10963907
Gottrup H, Andersen J, Arendt-Nielsen L, Jensen TS. Psychophysical examination in patients with post-mastectomy pain. Pain. 2000;87(3):275–84. 10.1016/S0304-3959(00)00291-8.10963907
18. Tait RC Zoberi K Ferguson M Persistent post-mastectomy pain: risk factors and current approaches to treatment J Pain. 2018 19 12 1367 1383 10.1016/j.jpain.2018.06.002 29966772
Tait RC, Zoberi K, Ferguson M, et al. Persistent post-mastectomy pain: risk factors and current approaches to treatment. J Pain. 2018;19(12):1367–83. 10.1016/j.jpain.2018.06.002.29966772
19. Schreiber KL Kehlet H Belfer I Edwards RR Predicting, preventing and managing persistent pain after breast cancer surgery: the importance of psychosocial factors Pain Manag. 2014 4 6 445 459 10.2217/pmt.14.33 25494696
Schreiber KL, Kehlet H, Belfer I, Edwards RR. Predicting, preventing and managing persistent pain after breast cancer surgery: the importance of psychosocial factors. Pain Manag. 2014;4(6):445–59. 10.2217/pmt.14.33.25494696
20. Belfer I Schreiber KL Shaffer JR Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors J Pain. 2013 14 10 1185 1195 10.1016/j.jpain.2013.05.002 23890847
Belfer I, Schreiber KL, Shaffer JR, et al. Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. J Pain. 2013;14(10):1185–95. 10.1016/j.jpain.2013.05.002.23890847
21. Schreiber KL Zinboonyahgoon N Flowers KM Prediction of persistent pain severity and impact 12 months after breast surgery using comprehensive preoperative assessment of biopsychosocial pain modulators [published correction appears in Ann Surg Oncol. 2021 Dec;28(Suppl 3):896] Ann Surg Oncol. 2021 28 9 5015 5038 10.1245/s10434-020-09479-2 33452600
Schreiber KL, Zinboonyahgoon N, Flowers KM, et al. Prediction of persistent pain severity and impact 12 months after breast surgery using comprehensive preoperative assessment of biopsychosocial pain modulators [published correction appears in Ann Surg Oncol. 2021 Dec;28(Suppl 3):896]. Ann Surg Oncol. 2021;28(9):5015–38. 10.1245/s10434-020-09479-2.33452600
22. Johannsen M Christensen S Zachariae R Jensen AB Socio-demographic, treatment-related, and health behavioral predictors of persistent pain 15 months and 7–9 years after surgery: a nationwide prospective study of women treated for primary breast cancer Breast Cancer Res Treat. 2015 152 3 645 658 10.1007/s10549-015-3497-x 26189085
Johannsen M, Christensen S, Zachariae R, Jensen AB. Socio-demographic, treatment-related, and health behavioral predictors of persistent pain 15 months and 7–9 years after surgery: a nationwide prospective study of women treated for primary breast cancer. Breast Cancer Res Treat. 2015;152(3):645–58. 10.1007/s10549-015-3497-x.26189085
23. van Helmond N Timmerman H van Dasselaar NT High body mass index is a potential risk factor for persistent postoperative pain after breast cancer treatment Pain Physician. 2017 20 5 E661 E671 28727711
van Helmond N, Timmerman H, van Dasselaar NT, et al. High body mass index is a potential risk factor for persistent postoperative pain after breast cancer treatment. Pain Physician. 2017;20(5):E661–71.28727711
24. Habib AS Kertai MD Cooter M Greenup RA Hwang S Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study Reg Anesth Pain Med. 2019 44 2 192 199 10.1136/rapm-2018-000040 30700614
Habib AS, Kertai MD, Cooter M, Greenup RA, Hwang S. Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study. Reg Anesth Pain Med. 2019;44(2):192–9. 10.1136/rapm-2018-000040.30700614
25. Feeney LR Tormey SM Harmon DC Breast cancer and chronic pain: a mixed methods review Ir J Med Sci. 2018 187 4 877 885 10.1007/s11845-018-1760-y 29404844
Feeney LR, Tormey SM, Harmon DC. Breast cancer and chronic pain: a mixed methods review. Ir J Med Sci. 2018;187(4):877–85. 10.1007/s11845-018-1760-y.29404844
26. Sheridan D Foo I O'Shea H Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer J Pain Symptom Manage. 2012 44 4 608 614 10.1016/j.jpainsymman.2011.10.021 22743155
Sheridan D, Foo I, O’Shea H, et al. Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer. J Pain Symptom Manage. 2012;44(4):608–14. 10.1016/j.jpainsymman.2011.10.021.22743155
27. Langford DJ Paul SM West C Persistent breast pain following breast cancer surgery is associated with persistent sensory changes, pain interference, and functional impairments J Pain. 2014 15 12 1227 1237 10.1016/j.jpain.2014.08.014 25439318
Langford DJ, Paul SM, West C, et al. Persistent breast pain following breast cancer surgery is associated with persistent sensory changes, pain interference, and functional impairments. J Pain. 2014;15(12):1227–37. 10.1016/j.jpain.2014.08.014.25439318
28. Ilhan E Chee E Hush J Moloney N The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review Pain. 2017 158 11 2082 2091 10.1097/j.pain.0000000000001004 28797014
Ilhan E, Chee E, Hush J, Moloney N. The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review. Pain. 2017;158(11):2082–91. 10.1097/j.pain.0000000000001004.28797014
29 Williams NR Williams S Kanapathy M Naderi N Vavourakis V Mosahebi A Radiation-induced fibrosis in breast cancer: a protocol for an observational cross-sectional pilot study for personalised risk estimation and objective assessment Int J Surg Protoc. 2019 14 9 13 10.1016/j.isjp.2019.02.002 31851743
Williams NR, Williams S, Kanapathy M, Naderi N, Vavourakis V, Mosahebi A. Radiation-induced fibrosis in breast cancer: a protocol for an observational cross-sectional pilot study for personalised risk estimation and objective assessment. Int J Surg Protoc. 2019;14:9–13. 10.1016/j.isjp.2019.02.002.31851743
30 Lukas A Theunissen M Boer DK AMAZONE: prevention of persistent pain after breast cancer treatment by online cognitive behavioral therapy-study protocol of a randomized controlled multicenter trial Trials. 2022 23 1 595 10.1186/s13063-022-06549-6 35879728
Lukas A, Theunissen M, Boer DK, et al. AMAZONE: prevention of persistent pain after breast cancer treatment by online cognitive behavioral therapy-study protocol of a randomized controlled multicenter trial. Trials. 2022;23(1):595. 10.1186/s13063-022-06549-6.35879728
31. Andersen KG Kehlet H Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention J Pain. 2011 12 7 725 746 10.1016/j.jpain.2010.12.005 21435953
Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011;12(7):725–46. 10.1016/j.jpain.2010.12.005.21435953
